Holen Sie sich die Stockscreener-App
0.9462
11.52%
-0.1238
Schlusskurs vom Vortag:
$1.07
Offen:
$0.9889
24-Stunden-Volumen:
1.57M
Relative Volume:
1.43
Marktkapitalisierung:
$94.59M
Einnahmen:
$1.63M
Nettoeinkommen (Verlust:
$-40.95M
KGV:
-1.6122
EPS:
-0.5869
Netto-Cashflow:
$-18.80M
1W Leistung:
+7.05%
1M Leistung:
+0.83%
6M Leistung:
-41.56%
1J Leistung:
+53.49%
1-Tages-Spanne:
$0.92
$0.9894
1-Wochen-Bereich:
$0.8901
$1.12
52-Wochen-Spanne:
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Firmenname
Rani Therapeutics Holdings Inc
Sektor
Branche
Telefon
(408) 457-3700
Adresse
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.9467 | 106.91M | 1.63M | -40.95M | -18.80M | -0.5869 |
VRTX
Vertex Pharmaceuticals Inc
|
436.54 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
636.30 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.34 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Lake Street | Buy |
| 2024-08-02 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-14 | Eingeleitet | Maxim Group | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-07-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Rani Therapeutics Holdings Inc Aktie (RANI) Neueste Nachrichten
Rani Therapeutics raises $20 million in direct offering - Investing.com
Rani Therapeutics to raise $20M in registered direct offering - MSN
Sovereign wealth fund leads $20M raise for oral drug delivery firm - Stock Titan
Rani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14 - MSN
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Rani Therapeutics Price Target Maintained With a $5.00/Share by Canaccord Genuity - Moomoo
Rani Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
RANI Maintained by Canaccord Genuity -- Price Target Stays at $5 - GuruFocus
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target - Investing.com
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target By Investing.com - Investing.com Canada
Insiders Enjoy US$582k Return After Buying Rani Therapeutics Holdings Stock - simplywall.st
Lake Street Initiates Rani Therapeutics(RANI.US) With Buy Rating, Announces Target Price $9 - Moomoo
Rani Therapeutics CFO Sanford to depart - MSN
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price - TipRanks
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition - The Manila Times
Rani Therapeutics Q1 Net Loss Narrows, Revenue Rises; CFO Svai Sanford to Step Down - Moomoo
RANI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Rani Therapeutics reports Q1 EPS (4c), consensus (5c) - TipRanks
Rani Therapeutics Sees Funding Sufficient Into 4Q27 >RANI - Moomoo
Rani Therapeutics CFO to depart, reports Q1 results - Investing.com UK
Rani Therapeutics CFO to depart, reports Q1 results By Investing.com - Investing.com South Africa
Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice - TipRanks
Rani Therapeutics Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
RANI: Q1 2026 saw clinical progress, leadership changes, and a reduced net loss year-over-year - TradingView
Rani Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Rani Therapeutics (RANI) posts Q1 2026 loss with new Chugai revenue and $43M cash - Stock Titan
Nasdaq warns Rani Therapeutics (NASDAQ: RANI) as CFO plans transition - Stock Titan
Oral biologics firm Rani trims Q1 loss; CFO to step down - Stock Titan
Rani Therapeutics Reports First Quarter 2026 Financial - GlobeNewswire
SymBiosis Capital holds 4.43M RANI shares, reports 4.4% stake (RANI) - Stock Titan
TradingKey - TradingKey
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference - The Manila Times
Rani Therapeutics (NASDAQ:RANI) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Rani Therapeutics Holdings Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
This Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last Year - Yahoo Finance
MSN Money - MSN
Rani Therapeutics (RANI) Projected to Post Earnings on Wednesday - MarketBeat
RANI Technical Analysis | Trend, Signals & Chart Patterns | RANI THERAPEUTICS HOLDINGS-A (NASDAQ:RANI) - ChartMill
RANI Price Today: Rani Therapeutics Holdings, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Rani Therapeutics | SCHEDULE 13G: Others - Moomoo
Vanguard Capital Management takes 5.12% stake in Rani Therapeutics (RANI) - Stock Titan
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Rani Therapeutics Holdings (RANI) price target decreased by 13.51% to 8.16 - MSN
Form DEF 14AOther definitive proxy statements - ADVFN
Finanzdaten der Rani Therapeutics Holdings Inc-Aktie (RANI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rani Therapeutics Holdings Inc-Aktie (RANI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| South Cone Investments Limited | 10% Owner |
Oct 21 '25 |
Sale |
2.77 |
4,000,000 |
11,074,000 |
2,379,194 |
| South Cone Investments Limited | 10% Owner |
Oct 20 '25 |
Sale |
2.41 |
1,923,000 |
4,637,314 |
6,379,194 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):